The combination medication is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to relieve symptoms and prevent exacerbations in adult patients. Shares of Astrazeneca Pharma India Ltd ended at ₹6,398, down by ₹372.60, or 5.50%, on the BSE.
